This revealed that 49.63% of the cases were categorized as Luminal A, 28.46% as Luminal B, 16.78% as triple-negative breast cancer (TNBC), and 5.1% as HER2+. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.